Hypoxia-Inducible Factor 2α: A Novel Target in Gliomas
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, HIF-1α (but not HIF-2α) has also been shown to enhance the self-renewal activity of stem-like U251 and U87 GBM cells and to inhibit the induction of differentiation suggesting that the HIF-α isoform dependency involved in the hypoxia-mediated maintenance of GBM stem-like cells may be cell type specific [50–52].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis
Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3963 · Cited by 296
RetractedProcollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis
Gilkes, D. M., Bajpai, S., Wong, C. C., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0629 · Cited by 252
RetractedGilkes, D. M., Xiang, L., Lee, S. J., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321510111 · Cited by 184
RetractedPonnala, S., Veeravalli, K. K., Chetty, C., Dinh, D. H., & Rao, J. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026191 · Cited by 24
RetractedWang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Hypoxia-Inducible Factor-1 (HIF-1)
Ke, Q., & Costa, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027029 · Cited by 1,646
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., McLendon, R. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.018 · Cited by 1,354
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,221
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9701 · Cited by 813
Gu, Y.-Z., Moran, S. M., Hogenesch, J. B., Wartman, L. D., & Bradfield, C. A. (1998) · Europe PMC (PubMed Central) · Cited by 769
Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response
Vaupel, P., & Harrison, L. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-4 · Cited by 761
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
Self-citationDigoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624
Takeda, N., O'Dea, E. L., Doedens, A., Kim, J.-W., Weidemann, A., Stockmann, C., Asagiri, M., Simon, M. C., Hoffmann, A., & Johnson, R. S. (2010) · Genes & Development · doi:10.1101/gad.1881410 · Cited by 623
Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
Nickerson, M. L., Jaeger, E., Shi, Y., Durocher, J. A., Mahurkar, S., Zaridze, D., Matveev, V., Janout, V., Kollarova, H., Bencko, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4921 · Cited by 588
Rong, Y., Durden, D. L., Van Meir, E. G., & Brat, D. J. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-200606000-00001 · Cited by 567
Mole, D. R., Blancher, C., Copley, R. R., Pollard, P. J., Gleadle, J. M., Ragoussis, J., & Ratcliffe, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901790200 · Cited by 552
Pietras, A., Katz, A. M., Ekström, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, N. M., Huse, J. T., & Holland, E. C. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.005 · Cited by 540
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
Brat, D. J., Castellano-Sanchez, A. A., Hunter, S. B., Pecot, M., Cohen, C., Hammond, E. H., Devi, S. N., Kaur, B., & Van Meir, E. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2073 · Cited by 485
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
Schödel, J., Grampp, S., Maher, E. R., Moch, H., Ratcliffe, P. J., Russo, P., & Mole, D. R. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.007 · Cited by 405
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases
Eltzschig, H. K., Bratton, D. L., & Colgan, S. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4422 · Cited by 366
Auffinger, B., Tobias, A. L., Han, Y., Lee, G., Guo, D., Dey, M., Lesniak, M. S., & Ahmed, A. U. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.31 · Cited by 349
Structural and functional analysis of hypoxia-inducible factor 1
Semenza, G. L., Agani, F., Booth, G., Forsythe, J., Iyer, N., Jiang, B.-H., Leung, S., Roe, R., Wiener, C., & Yu, A. (1997) · Kidney International · doi:10.1038/ki.1997.77 · Cited by 343
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336
Axelson, H., Fredlund, E., Ovenberger, M., Landberg, G., & Påhlman, S. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2005.03.007 · Cited by 312
Investigating hypoxic tumor physiology through gene expression patterns
Denko, N. C., Fontana, L. A., Hudson, K. M., Sutphin, P. D., Raychaudhuri, S., Altman, R., & Giaccia, A. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206703 · Cited by 305
Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor
Scheuermann, T. H., Tomchick, D. R., Machius, M., Guo, Y., Bruick, R. K., & Gardner, K. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808092106 · Cited by 301
Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells
Colwell, N., Larion, M., Giles, A. J., Seldomridge, A. N., Sizdahkhani, S., Gilbert, M. R., & Park, D. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now258 · Cited by 284
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors
Xia, Y., Choi, H.-K., & Lee, K. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.033 · Cited by 278
Targeting Transcription Factors in Cancer
Bhagwat, A. S., & Vakoc, C. R. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.001 · Cited by 276
Sathornsumetee, S., Cao, Y., Marcello, J. E., Herndon, J. E., McLendon, R. E., Desjardins, A., Friedman, H. S., Dewhirst, M. W., Vredenburgh, J. J., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3652 · Cited by 261
HIF-1 in cancer therapy: two decade long story of a transcription factor
Soni, S., & Padwad, Y. S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1301680 · Cited by 251
Primary Glioblastomas Express Mesenchymal Stem-Like Properties
Tso, C.-L., Shintaku, P., Chen, J., Liu, Q., Liu, J., Chen, Z., Yoshimoto, K., Mischel, P. S., Cloughesy, T. F., Liau, L. M., et al. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0005 · Cited by 233
Cooper, L. A. D., Gutman, D. A., Chisolm, C., Appin, C., Kong, J., Rong, Y., Kurc, T., Van Meir, E. G., Saltz, J. H., Moreno, C. S., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.01.040 · Cited by 230
Erbel, P. J. A., Card, P. B., Karakuzu, O., Bruick, R. K., & Gardner, K. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2533374100 · Cited by 228
Chaturvedi, P., Gilkes, D. M., Takano, N., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406655111 · Cited by 226
Ferrandina, G., Zannoni, G. F., Martinelli, E., Paglia, A., Gallotta, V., Mozzetti, S., Scambia, G., & Ferlini, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2715 · Cited by 219
Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
Yu, T., Tang, B., & Sun, X. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.3.489 · Cited by 191
Necrosis and Glioblastoma: A Friend or a Foe? A Review and a Hypothesis
Raza, S. M., Lang, F. F., Aggarwal, B. B., Fuller, G. N., Wildrick, D. M., & Sawaya, R. (2002) · Neurosurgery · doi:10.1097/00006123-200207000-00002 · Cited by 167
Hurwitz, H. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.s.010 · Cited by 165
VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
Cowey, C. L., & Rathmell, W. K. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0015-5 · Cited by 165
Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2362-z · Cited by 159
Studies of Tissue PO2 in Normal and Pathological Human Brain Cortex
Meixensberger, J., Dings, J. T. A., Kuhnigk, H., & Roosen, K. (1993) · Springer eBooks · doi:10.1007/978-3-7091-9302-0_10 · Cited by 140
Taylor, C. T., & McElwain, J. C. (2010) · Physiology · doi:10.1152/physiol.00029.2010 · Cited by 135
In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas
Toledo, R. A., Qin, Y., Srikantan, S., Morales, N. P., Li, Q., Deng, Y., Kim, S.-W., Pereira, M. A. A., Toledo, S. P. A., Su, X., et al. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0101 · Cited by 134
Lee, G., Auffinger, B., Guo, D., Hasan, T., Deheeger, M., Tobias, A. L., Kim, J. Y., Atashi, F., Zhang, L., Lesniak, M. S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0675 · Cited by 132
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI
Gerstner, E. R., Zhang, Z., Fink, J. R., Muzi, M., Hanna, L., Greco, E., Prah, M., Schmainda, K. M., Mintz, A., Kostakoglu, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2529 · Cited by 122
Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy
Rey, S., Schito, L., Wouters, B. G., Eliasof, S. D., & Kerbel, R. S. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.05.002 · Cited by 122
Johansson, E., Grassi, E. S., Pantazopoulou, V., Tong, B., Lindgren, D., Berg, T. J., Pietras, E. J., Axelson, H., & Pietras, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.049 · Cited by 121
The impact of hemoglobin levels on treatment outcomes in patients with cancer
Littlewood, T. J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90213-1 · Cited by 117
Intratumoral oxygen pressure in malignant brain tumor
Kayama, T., Yoshimoto, T., Fujimoto, S., & Sakurai, Y. (1991) · Journal of Neurosurgery · doi:10.3171/jns.1991.74.1.0055 · Cited by 116
Schöning, J. P., Monteiro, M., & Gu, W. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12693 · Cited by 115
Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression
Brat, D. J., & Mapstone, T. B. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00014 · Cited by 111
Kaluz, S., Kaluzová, M., & Stanbridge, E. J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00552-06 · Cited by 108
Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis
Kim, Y. W., Koul, D., Kim, S. H., Lucio-Eterovic, A. K., Freire, P. R., Yao, J. C., Wang, J., Almeida, J. S., Aldape, K., & Yung, W. K. A. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not024 · Cited by 102
Slemc, L., & Kunej, T. (2016) · Tumor Biology · doi:10.1007/s13277-016-5331-4 · Cited by 100
Glioma Stem Cell Maintenance: The Role of the Microenvironment
Heddleston, J. M., Hitomi, M., Venere, M., Flavahan, W. A., Yang, K., Kim, Y., Minhas, S., Rich, J. N., & Hjelmeland, A. B. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797249260 · Cited by 98
Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma
Dong, S., Nutt, C. L., Betensky, R. A., Stemmer-Rachamimov, A. O., Denko, N. C., Ligon, K. L., Rowitch, D. H., & Louis, D. N. (2005) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000186940.14779.90 · Cited by 96
Yeo, E.-J., Ryu, J.-H., Cho, Y.-S., Chun, Y.-S., Huang, L. E., Kim, M.-S., & Park, J.-W. (2006) · Blood · doi:10.1182/blood-2005-06-2564 · Cited by 81
Pietras, A., Johnsson, A. S., & Påhlman, S. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_72 · Cited by 68
Mao, X., Yan, M., Xue, X., Zhang, X., Ren, H.-G., Guo, G., Wang, P., Zhang, W., & Huo, J. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.56 · Cited by 64
D’Alessio, A., Proietti, G., Lama, G., Biamonte, F., Lauriola, L., Moscato, U., Vescovi, A. L., Mangiola, A., Angelucci, C., & Sica, G. (2016) · Oncotarget · doi:10.18632/oncotarget.12398 · Cited by 61
Toledo, R. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0479 · Cited by 48
Hypoxia-Inducible Factor 1 as a Possible Target for Cancer Chemoprevention
López‐Lázaro, M. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0369 · Cited by 47
Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas
Yamamoto, Y., Maeda, Y., Kawai, N., Kudomi, N., Aga, F., Ono, Y., & Nishiyama, Y. (2012) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3283529984 · Cited by 46
Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α.
Tibes, R., Falchook, G. S., Von Hoff, D. D., Weiss, G. J., Iyengar, T., Kurzrock, R., Pestano, L., Lowe, A. M., & Herbst, R. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3076 · Cited by 46
Bordji, K., Grandval, A., Cuhna-Alves, L., Lechapt, E., & Bernaudin, M. (2014) · FEBS Journal · doi:10.1111/febs.13062 · Cited by 44
Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1α eradicates gliomas
Sun, X., Liu, M., Wei, Y., Liu, F., Zhi, X., Xu, R., & Krissansen, G. W. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700907 · Cited by 41
HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma
Wang, X., Dong, J., Jia, L., Zhao, T., Lang, M., Li, Z., Lan, C., Li, X., Hao, J., Wang, H., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.032 · Cited by 40
Rimkus, T. K., Carpenter, R. L., Sirkisoon, S. R., Zhu, D., Pasche, B., Chan, M. D., Lesser, G. J., Tatter, S. B., Watabe, K., Debinski, W., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2933 · Cited by 38
Self-citationKatsetos, C. D., Dráber, P., & Kavallaris, M. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011797378760 · Cited by 29
HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma
Zhuang, Z., Yang, C., Ryška, A., Ji, Y., Hou, Y., Graybill, S. D., Bullova, P., Lubensky, I. A., Klöppel, G., & Pacák, K. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0148 · Cited by 28
Kirkpatrick, J. P., Desjardins, A., Quinn, J. A., Rich, J. N., Vredenburgh, J. J., Sathornsumetee, S., Gururangan, S., Sidor, C. F., Friedman, H. S., & Reardon, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.2065 · Cited by 12
Research works printed but not linked: 2
- 10.1128/mcb.12.12.5447-5454.1992 · doi:10.1128/mcb.12.12.5447-5454.1992 · Paper page
- Wallace E . PT2385: HIF-2a antagonist for the treatment of VHL mutant ccRCC. Proceedings of : 12th International VHL Medical Symposium. MA, USA, 7–9 April 2016 .
Cited by
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy
Tang, X., Zuo, C., Fang, P., Liu, G., Qiu, Y., Huang, Y., & Tang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701291 · Cited by 140
Yin, J., Ge, X. Q., Shi, Z., Chen, Y., Lu, C., Wei, Y., Zeng, A., Wang, X., Yan, W., Zhang, J., et al. (2020) · Theranostics · doi:10.7150/thno.47057 · Cited by 113
Hypoxia-mediated cancer stem cell resistance and targeted therapy
Sun, X., Lv, X., Yan, Y., Zhao, Y., Ma, R., He, M., & Wei, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110623 · Cited by 99
Metadata
- Authors
- Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E.
- Affiliations
- Atrium Health Wake Forest Baptist (US)
- Mayo Clinic (US)
- Brain Tumor Center of Excellence Wake Forest Comprehensive Cancer Center Winston-Salem NC 27157 USA
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2018-08-09
- Volume
- 10
- Issue
- 18
- Pages
- 2227-2236
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- PMC
- PMC6479274
- OpenAlex
- W2886561153
- Cited by
- 40
- References
- 85
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 1 · 2018: 1
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Future Medicinal Chemistry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA012197)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-2α, glioblastoma, glioma stem cells, tumor hypoxia, PT2385, targeted cancer therapy, drug resistance
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Glioma, Humans, Indans, Sulfones, RNA Interference, RNA, Small Interfering, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.